{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-25-000028","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.170930+00:00","generated_at":"2026-05-21T05:13:40.105874+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026","bullets":["Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.","Cash at March 31, 2025: $31.1M, down from $36.7M at December 31, 2024.","Revenue was $0 compared to $1.0M in the prior-year period.","Phase 3 CATT1 trial for cadisegliatin shortened from 12 to 6 months; topline data expected in 2H 2026.","R&D expenses $2.8M, G&A $3.7M; operating loss of $6.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-25-000028","json":"https://secwatch.observer/filing/0001641489-25-000028.json","markdown":"https://secwatch.observer/filing/0001641489-25-000028.md","text":"https://secwatch.observer/filing/0001641489-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/0001641489-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/vtvt-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:13:40.105874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}